51
|
Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration. Future Med Chem 2017; 9:765-780. [DOI: 10.4155/fmc-2017-0014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Melatonin is an indoleamine produced mainly in the pineal gland. The natural decline of melatonin levels with aging strongly contributes to the development of neurodegenerative disorders. Pleiotropic actions displayed by melatonin prevent several processes involved in neurodegeneration such as neuroinflammation, oxidative stress, excitotoxicity and/or apoptosis. This review focuses on a number of melatonin hybrids resulting from the juxtaposition of tacrine, berberine, tamoxifen, curcumin, N,N-dibenzyl(N-methyl)amine, among others, with potential therapeutic effects for the treatment of neurodegenerative diseases.
Collapse
|
52
|
Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. Eur J Med Chem 2017; 132:294-309. [PMID: 28371641 DOI: 10.1016/j.ejmech.2017.03.062] [Citation(s) in RCA: 216] [Impact Index Per Article: 30.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Revised: 03/13/2017] [Accepted: 03/25/2017] [Indexed: 12/25/2022]
Abstract
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders with notable factor of dysfunction in cholinergic system. Low ACh level can be observed in the pathogenesis of AD. Several AChE inhibitors have already been used for clinical treatments. However, other than normal conditions, ACh is mostly hydrolyzed by BuChE in progressed AD. Account for an increased level of BuChE and decreased level of AChE in the late stage of AD, development of selective BuChE inhibitor is of vital importance. Up till now, compounds with various scaffolds have been discovered to selectively inhibit BuChE. Different effective anti-BuChE molecules are concluded in this review.
Collapse
Affiliation(s)
- Qi Li
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Hongyu Yang
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China
| | - Yao Chen
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China
| | - Haopeng Sun
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China.
| |
Collapse
|
53
|
Benchekroun M, Romero A, Egea J, León R, Michalska P, Buendía I, Jimeno ML, Jun D, Janockova J, Sepsova V, Soukup O, Bautista-Aguilera OM, Refouvelet B, Ouari O, Marco-Contelles J, Ismaili L. The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. J Med Chem 2016; 59:9967-9973. [PMID: 27736061 DOI: 10.1021/acs.jmedchem.6b01178] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Novel multifunctional tacrines for Alzheimer's disease were obtained by Ugi-reaction between ferulic (or lipoic acid), a melatonin-like isocyanide, formaldehyde, and tacrine derivatives, according to the antioxidant additive approach in order to modulate the oxidative stress as therapeutic strategy. Compound 5c has been identified as a promising permeable agent showing excellent antioxidant properties, strong cholinesterase inhibitory activity, less hepatotoxicity than tacrine, and the best neuroprotective capacity, being able to significantly activate the Nrf2 transcriptional pathway.
Collapse
Affiliation(s)
- Mohamed Benchekroun
- Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, Université Bourgogne Franche-Comté , 19 rue Ambroise Paré, CS 25000 Besançon, France
| | - Alejandro Romero
- Department of Toxicology & Pharmacology, Faculty of Veterinary Medicine, Complutense University of Madrid , E-28040 Madrid, Spain
| | - Javier Egea
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario La Princesa , C/Diego de León 62, E-28006 Madrid, Spain.,Instituto de I+D del Medicamento Teófilo Hernando (ITH), Facultad de Medicina, Universidad Autónoma de Madrid , C/Arzobispo Morcillo 4, E-28029 Madrid, Spain
| | - Rafael León
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario La Princesa , C/Diego de León 62, E-28006 Madrid, Spain.,Instituto de I+D del Medicamento Teófilo Hernando (ITH), Facultad de Medicina, Universidad Autónoma de Madrid , C/Arzobispo Morcillo 4, E-28029 Madrid, Spain
| | - Patrycja Michalska
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario La Princesa , C/Diego de León 62, E-28006 Madrid, Spain.,Instituto de I+D del Medicamento Teófilo Hernando (ITH), Facultad de Medicina, Universidad Autónoma de Madrid , C/Arzobispo Morcillo 4, E-28029 Madrid, Spain
| | - Izaskun Buendía
- Instituto de Investigación Sanitaria, Servicio de Farmacología Clínica, Hospital Universitario La Princesa , C/Diego de León 62, E-28006 Madrid, Spain.,Instituto de I+D del Medicamento Teófilo Hernando (ITH), Facultad de Medicina, Universidad Autónoma de Madrid , C/Arzobispo Morcillo 4, E-28029 Madrid, Spain
| | - María Luisa Jimeno
- Centro Química Orgánica "Lora-Tamayo" (CENQUIOR), CSIC , C/Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Daniel Jun
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence , CZ-500 01 Hradec Kralove, Czech Republic
| | - Jana Janockova
- Biomedical Research Center, University Hospital Hradec Kralove , CZ-500 05 Hradec Kralove, Czech Republic
| | - Vendula Sepsova
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence , CZ-500 01 Hradec Kralove, Czech Republic
| | - Ondrej Soukup
- Biomedical Research Center, University Hospital Hradec Kralove , CZ-500 05 Hradec Kralove, Czech Republic
| | - Oscar M Bautista-Aguilera
- Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, Université Bourgogne Franche-Comté , 19 rue Ambroise Paré, CS 25000 Besançon, France
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, Université Bourgogne Franche-Comté , 19 rue Ambroise Paré, CS 25000 Besançon, France
| | - Olivier Ouari
- ICR UMR 7273, Aix Marseille University, CNRS , 13013 Marseille, France
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry, IQOG, CSIC , C/Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Laboratoire de Chimie Organique et Thérapeutique, UFR SMP, Université Bourgogne Franche-Comté , 19 rue Ambroise Paré, CS 25000 Besançon, France
| |
Collapse
|